1 Value Stock with Exciting Potential and 2 We Brush Off
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Separating the winners from the value traps is a tough challenge, and that’s where StockStory comes in. Our job is to find you high-quality companies that will stand the test of time. Keeping that in mind, here is one value stock trading at a big discount to its intrinsic value and two facing an uphill battle.
Two Value Stocks to Sell:
Lennar (LEN)
Forward P/E Ratio: 14.8x
One of the largest homebuilders in America, Lennar (NYSE:LEN) is known for constructing affordable, move-up, and retirement homes across a range of markets and communities.
Why Do We Steer Clear of LEN?
- Sales pipeline suggests its future revenue growth won’t meet our standards as its backlog averaged 9.2% declines over the past two years
- Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 8.9% annually
- Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability
Lennar is trading at $83.73 per share, or 14.8x forward P/E. Read our free research report to see why you should think twice about including LEN in your portfolio.
Jazz Pharmaceuticals (JAZZ)
Forward P/E Ratio: 9.8x
Originally founded in 2003 and now headquartered in Ireland following a 2012 tax inversion merger, Jazz Pharmaceuticals (NASDAQGS:JAZZ) develops and markets medicines for sleep disorders, epilepsy, and cancer, with a focus on treatments for patients with limited therapeutic options.
Why Are We Cautious About JAZZ?
- Costs have risen faster than its revenue over the last five years, causing its adjusted operating margin to decline by 2.6 percentage points
- ROIC of 2.7% reflects management’s challenges in identifying attractive investment opportunities
Jazz Pharmaceuticals’s stock price of $246.81 implies a valuation ratio of 9.8x forward P/E. Dive into our free research report to see why there are better opportunities than JAZZ.
One Value Stock to Buy:
Permian Resources (PR)
Forward P/E Ratio: 10.3x
Controlling roughly 450,000 net acres in America's most productive oil patch, Permian Resources (NYSE:PR) is an oil and natural gas producer that drills wells and extracts hydrocarbons from underground reservoirs in West Texas and New Mexico.
Why Is PR a Good Business?
- Annual revenue growth of 47.2% over the last ten years was superb and indicates its market share increased during this cycle
- Attractive asset base leads to wonderful unit economics and a best-in-class gross margin of 76.1%
- Robust free cash flow margin of 29.7% gives it many options for capital deployment
At $23.58 per share, Permian Resources trades at 10.3x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.
Stocks We Like Even More
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.